文献速递垂体与肾上腺疾病

垂体炎结局及预测糖皮质激素治疗反应性的因素:一项前瞻性双臂研究

Hypophysitis Outcome and Factors Predicting Responsiveness to Glucocorticoid Therapy: A Prospective and Double-Arm Study.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

糖皮质激素治疗组垂体功能改善/恢复率高于未治疗组(58.3% vs 25%,P=0.04),且治疗反应性与抗垂体抗体阳性、诊断时尿崩症、T1加权像神经垂体亮斑缺失及垂体柄增粗>3.9 mm相关。

要点

  • 糖皮质激素治疗可改善PAH患者垂体功能,治疗组改善率58.3%高于未治疗组25%。
  • 抗垂体抗体阳性、尿崩症、亮斑缺失及垂体柄>3.9 mm预测治疗反应。
  • 未治疗患者中未发现 predicting 结局的因素。

核心结论

  • 糖皮质激素治疗垂体炎可改善垂体分泌功能,应结合内分泌、免疫和形态学预测标志物评估后鼓励使用。

研究设计与样本

  • 干预为口服泼尼松50 mg/d或保守观察策略。

主要发现

  • 2年时PAH改善/恢复在治疗组8例(66.7%)、未治疗组2例(25%)。
  • PAH恶化在未治疗组3例(37.5%),稳定在治疗组4例(33.3%)和未治疗组3例(37.5%)。
  • 垂体功能改善/恢复在治疗组58.3%,未治疗组25%(P=0.04)。
  • 治疗反应性与抗垂体抗体存在(P=0.01)、诊断时尿崩症(P=0.01)、T1加权像神经垂体亮斑缺失(P=0.01)及垂体柄视交叉处>3.9 mm(AUC 0.97,敏感性100%,特异性100%;P=0.04)相关。

关键数值与推荐

  • 垂体柄视交叉处>3.9 mm预测治疗反应:AUC 0.97,敏感性100%,特异性100%(P=0.04)。
  • 抗垂体抗体阳性、诊断时尿崩症、T1加权像亮斑缺失均与治疗反应性相关(P=0.01)。

临床怎么用

  • 对PAH患者,可评估抗垂体抗体、尿崩症、神经垂体亮斑及垂体柄厚度以预测糖皮质激素治疗反应。
  • 糖皮质激素治疗可能改善垂体功能,但需结合预测标志物个体化决策。

局限性

  • 未治疗患者中未识别出预测结局的因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Primary autoimmune hypophysitis (PAH) evolves in most untreated cases in irreversible hypopituitarism. PAH outcome, instead, after immunosuppressive treatment has not been completely clarified. OBJECTIVE: To evaluate hypophysitis and pituitary function outcomes. DESIGN: A prospective, double-arm study with a 2-year follow-up. SETTING: Referral center for pituitary disease. PATIENTS: Twenty PAH cases. INTERVENTIONS: Oral prednisone 50 mg/d or conservative strategy by observation. MAIN OUTCOME MEASURES: Primary endpoint was the improvement/stabilization/worsening of PAH from baseline to a 2-year visit. Secondary endpoint was the improvement/stabilization/worsening of pituitary function from baseline to a 2-year visit. RESULTS: Twelve patients (57.1%) were treated with a glucocorticoid-immunosuppressive therapy, and eight patients (42.9%) were observed. At the 2-year visit, PAH improvement/recovery occurred in eight immunosuppressive-treated (66.7%) patients and in two untreated patients (25%). PAH worsened in three untreated patients (37.5%) and was considered stable in four immunosuppressive-treated (33.3%) and three untreated patients (37.5%). Improvement/recovery of pituitary function occurred more frequently in immunosuppressive-treated patients (58.3%) compared with untreated ones (25%; P = 0.04). Responsiveness to immunosuppressive treatment is correlated with antipituitary antibody presence (P = 0.01), occurrence of diabetes insipidus at PAH diagnosis (P = 0.01), absence of the physiological neuropituitary "bright spot" on T1-weighed images (P = 0.01), and pituitary stalk at optical chiasm larger than 3.9 mm (area under the curve: 0.97, sensibility: 100%, specificity: 100%; P = 0.04). On the other hand, we failed to identify factors predicting the outcome, among untreated patients. CONCLUSIONS: Glucocorticoid treatment of hypophysitis improves pituitary secretion and should be encouraged in accordance with the evaluation of endocrine-, immunological-, and morphological-predictive markers.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chiloiro S, Tartaglione T, Capoluongo ED, et al. Hypophysitis Outcome and Factors Predicting Responsiveness to Glucocorticoid Therapy: A Prospective and Double-Arm Study. J Clin Endocrinol Metab. 2018. PMID: 30085134. doi:10.1210/jc.2018-01021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。